A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
Learn more: Researchers develop a novel RNA-based therapy to target West Nile Virus
The Latest on: RNA therapy
[google_news title=”” keyword=”RNA therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: RNA therapy
- Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBCon April 26, 2024 at 6:00 am
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's ...
- Two RNA-binding proteins could contribute to cancer therapy developmenton April 26, 2024 at 2:08 am
Highlighting the differences between the two RNA-binding proteins for the first time and their role in cancer development, researchers hope that their research can provide new avenues for drugs to ...
- Oligonucleotides and mRNA vaccines dominate in strategic alliances for RNA therapies : GlobalDataon April 26, 2024 at 1:53 am
Global data expert forecast that RNA-therapies hold great promise for combating human diseases such as infectious diseases, cancer, neurodegeneration, metabolic disorders, and rare genetic diseases.
- Cow's milk particles unlock one of medicine’s most challenging puzzleson April 26, 2024 at 12:47 am
Cow’s milk contains nanoparticles that can be used to deliver disease-modifying RNA therapy orally, according to a new study. With RNA-based drugs currently only administrable by injection, the ...
- This AI Just Designed a More Precise CRISPR Gene Editor for Human Cells From Scratchon April 25, 2024 at 1:25 pm
Based on large language models—the tech behind the popular ChatGPT—Profluent's AI designed a new gene editor and put it to work in human cells.
- RNA Therapies in Oncology: Analytical Tool Covers Over 127 Companies and Their Partners, Currently Developing 274 RNA Therapy Drugson April 25, 2024 at 6:39 am
The "RNA Therapies in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.RNA therapies, such as miRNA, RNAi & siRNA, is an emerging class of biopharmaceutical that ...
- Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in Crohn’s diseaseon April 25, 2024 at 6:00 am
Whether human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) could heal luminal ulcers in Crohn’s disease.
- New potential avenues for cancer therapies through RNA-binding proteinson April 24, 2024 at 10:41 am
A new paper describes the role of two RNA-binding proteins in the development of sarcoma and carcinoma cancers, highlighting the important and emerging role of RNA-binding proteins in cancer research ...
- A new method for enzymatic synthesis of potential RNA therapeuticson April 23, 2024 at 9:10 am
A team of researchers at IOCB Prague led by Prof. Michal Hocek has developed a novel method for preparing ribonucleic acid (RNA) containing modified bases. Innovative use of engineered DNA polymerases ...
via Bing News